Protein kinase Cepsilon contributes to regulation of the sarcolemmal Na+-K+ pump

Kerrie A. Buhagiar1,2, Peter S. Hansen1,2, Nerida L. Bewick1, and Helge H. Rasmussen1,2

1 Department of Cardiology, Royal North Shore Hospital, and 2 University of Sydney, Sydney, New South Wales, Australia 2065


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A reduction in angiotensin II (ANG II) in vivo by treatment of rabbits with the angiotensin-converting enzyme inhibitor, captopril, increases Na+-K+ pump current (Ip) of cardiac myocytes. This increase is abolished by exposure of myocytes to ANG II in vitro. Because ANG II induces translocation of the varepsilon -isoform of protein kinase C (PKCvarepsilon ), we examined whether this isozyme regulates the pump. We treated rabbits with captopril, isolated myocytes, and measured Ip of myocytes voltage clamped with wide-tipped patch pipettes. Ip of myocytes from captopril-treated rabbits was larger than Ip of myocytes from controls. ANG II superfusion of myocytes from captopril-treated rabbits decreased Ip to levels similar to controls. Inclusion of PKCvarepsilon -specific blocking peptide in pipette solutions used to perfuse the intracellular compartment abolished the effect of ANG II. Inclusion of psi varepsilon RACK, a PKCvarepsilon -specific activating peptide, in pipette solutions had an effect on Ip that was similar to that of ANG II. There was no additive effect of ANG II and psi varepsilon RACK. We conclude that PKCvarepsilon regulates the sarcolemmal Na+-K+ pump.

intracellular sodium; protein kinase C isozymes; cardiac myocytes; angiotensin; cardiac hypertrophy


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

IT IS WIDELY BELIEVED that the protein kinase C (PKC) family of isozymes is involved in the control of the membrane Na+-K+ pump (see Ref. 30 for review). Multiple, very diverse isozymes of PKC are known to exist. They differ in their cellular location, site of translocation upon activation, sensitivity to cell Ca2+, lipid activators, pharmacological blockers and activators, and in their functional role within the cell. Evidence is also emerging that indicates that isozymes of PKC differ in their involvement in disease processes, and it has been suggested that isozyme-specific stimulation or inhibition of PKC may have a role in the treatment of a variety of diseases (3, 5).

Establishing a link between isozymes of PKC and regulation of the sarcolemmal Na+-K+ pump is important because the pump plays a pivotal role in cell function. The pump is the main determinant of low cytosolic levels of Na+. It is widely appreciated that this, in turn, drives secondary active transmembrane transport of other ions and of a variety of organic compounds. Cell volume, metabolism, excitation, and excitation-contraction coupling depend on these processes (30). However, it has also become apparent that the Na+-K+ pump has an even more broadly based role in cell function, at least in the heart. Pump inhibition induces activation of key growth-related cardiac genes and generation of reactive oxygen species (see Refs. 14 and 31 and references therein). The Na+-K+ pump may, therefore, represent an important link between specific isozymes of PKC and cardiac function and disease. We examined whether PKC isoform-specific regulation of the sarcolemmal Na+-K+ pump can be identified.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Treatment protocols and experimental design. Male New Zealand White rabbits that weighed 2.5-3.0 kg were given the angiotensin-converting enzyme (ACE) inhibitor captopril in their drinking water for 8 days (11) to reduce background levels of angiotensin II (ANG II). Control rabbits were given captopril-free water. At the completion of treatment, rabbits were anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine hydrochloride (20 mg/kg), the heart was excised, and single ventricular myocytes were isolated as described previously (11). Treatment with captopril caused an increase in electrogenic Na+-K+ current (Ip) measured in the isolated myocytes. The increase was abolished by in vitro exposure to ANG II (1, 10). To examine whether a specific isoform of PKC can be implicated in the regulation of the sarcolemmal Na+-K+ pump, we used this effect of ANG II to induce a decrease in Ip of myocytes isolated from rabbits treated with captopril.

Measurement of Ip. We used the whole cell patch-clamp technique to measure Ip. Myocytes were initially superfused with modified Tyrode solution warmed to 35 ± 0.5°C. The solution contained (in mM) 140 NaCl, 5.6 KCl, 2.16 CaCl2, 1 MgCl2, 0.44 NaH2PO4, 10 glucose, and 10 HEPES, pH 7.40 ± 0.01 at 35°C. When the whole cell configuration had been established, we switched to a superfusate that was identical, except it was nominally Ca2+ free and contained 0.2 mM CdCl2 to reduce Na+/Ca2+ exchange current and 2 mM BaCl2 to block K+ channel currents. When indicated, this solution contained ANG II in a concentration of 1 µM. Ip was measured at a membrane voltage of -40 mV to block voltage-sensitive Na+ channels. The inhibition of non-pump membrane currents facilitates accurate identification of Ip.

Myocytes were patch clamped with wide-tipped (4-5 µm) pipettes as described (1) to facilitate rapid equilibration of solutes between patch pipette solutions and the intracellular compartment. Pipette solutions contained (in mM) 70 potassium glutamate, 1 KH2PO4, 5 HEPES, 2 MgATP, 5 EGTA, 10 sodium glutamate, and 70 tetramethylammonium chloride (TMA-Cl), pH 7.05 ± 0.01 at 35°C. Filled patch pipettes had resistances of 0.8-1.1 MOmega . In some experiments, we included PKC isozyme-specific inhibiting and activating peptides in pipette solutions. The peptides were dissolved in water, and aliquots were stored at -20°C. They were added to pipette solutions on the day of experimentation to achieve a final concentration of 100 nM.

Membrane currents were recorded using the continuous single-electrode voltage-clamp mode of an Axoclamp-2B amplifier and AxoTape or pCLAMP software (Axon Instruments, Foster City, CA). Ip was identified as the shift in holding current induced by ouabain. Experiments were included in the analysis when no drift in holding currents could be identified on the digital display of the voltage-clamp amplifier for at least 50 s before and after exposure to ouabain. Holding currents were measured by sampling with an electronic cursor every 5 s over these two 50-s periods. The mean of these samples defined the holding current before and after exposure to ouabain. Ip is reported as normalized for membrane capacitance and hence cell size.

Reagents and chemicals. TMA-Cl was "purum" grade and purchased from Fluka (Switzerland). Other chemicals were analytical grade and purchased from BDH (Australia). ANG II and ouabain were purchased from Sigma Chemical (St. Louis, MO). Captopril was purchased from Bristol-Myers Squibb Pharmaceuticals (Australia). PKC-inhibiting and -activating peptides were kindly provided by Professor D. Mochly-Rosen (Stanford University School of Medicine, Stanford, CA).

Statistical analysis. Results are expressed as means ± SE. One-way ANOVA was used for statistical comparisons. Where the same control group was used in more than one comparison, Dunnett's test was used to compare groups. P < 0.05 is regarded as significant in all comparisons.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Effect of ANG II on Ip. In previous studies, an increase in Ip induced by in vivo treatment of rabbits with the ACE inhibitor captopril could be abolished by in vitro exposure of myocytes to 10 nM ANG II for 45 min before the whole cell configuration was established (1, 10). In the present study, PKC-inhibiting and -activating peptides had to diffuse from patch pipette solutions into the intracellular compartment before myocytes were exposed to ANG II. Maintaining the whole cell configuration for 45 min is difficult. In initial experiments, we therefore examined whether a decrease in Ip could be induced with brief exposure of myocytes to ANG II after the whole cell configuration had been established.

To facilitate rapid binding to receptors and activation of intracellular messengers before measurement of Ip, we used ANG II in a concentration of 1 µmol/l rather than the 10 nM used previously. We isolated myocytes from rabbits treated with captopril. When the whole cell configuration had been established, we measured membrane capacitance while the myocytes were superfused with Ca2+-containing solution. This solution was ANG II free. We then switched to a superfusate that was Ca2+ free and contained Ba2+, Cd2+, and ANG II. The myocytes were exposed to this solution for 10 min before Ip was identified as the shift in holding current, induced by switching to a solution that also included 100 µM ouabain. Superfusion of ouabain in these and all other experiments was started 14 min after the whole cell configuration had been established.

Tracings of representative changes in membrane currents induced by ouabain recorded in myocytes exposed or not exposed to ANG II are shown in Fig. 1. The ouabain-induced shift in current was smaller for a myocyte exposed to ANG II than a myocyte superfused with ANG II-free solution throughout the experiment. A summary of mean levels of Ip determined in all such experiments is shown in Fig. 2. Figure 2 also shows the mean levels of Ip determined for myocytes isolated from untreated control rabbits. In agreement with previous findings (1, 10), treatment with captopril induced a significant increase in Ip. Exposure of myocytes isolated from captopril-treated rabbits to ANG II induced a decrease in Ip to a level similar to that recorded in myocytes isolated from untreated control rabbits and not exposed to ANG II in vitro. The level was also similar to the mean Ip of myocytes isolated from rabbits treated with captopril and exposed to 10 nM ANG II for 45 min before the whole cell configuration was established (1, 10). We conclude that the cellular messenger mechanisms linking the ANG II receptor to the Na+-K+ pump remain intact after the whole cell configuration has been established and that brief exposure of patch-clamped myocytes to ANG II causes an easily detectable decrease in Ip. We used this response of Ip to examine whether an isoform of PKC can be implicated in the regulation of the Na+-K+ pump.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   Shifts in holding current (Ih) induced by 100 µM ouabain. Myocytes were isolated from captopril-treated rabbits (Cap). Cells with a similar capacitance (Cm) were chosen to facilitate comparisons. The shift in Ih, and hence Na+-K+ pump current (Ip), was smaller for the myocyte exposed to angiotensin II (Cap + ANG II) than for the myocyte not exposed. Inclusion of the protein kinase Cvarepsilon (PKCvarepsilon )-blocking peptide (Cap + ANG II + varepsilon -inh) in pipette solutions resulted in an Ip similar to that for the myocyte not exposed to ANG II. Inh, inhibiting.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   ANG II-induced pump inhibition and PKCvarepsilon . Numbers in parentheses indicate the number of myocytes. Myocytes represented in each bar were obtained from at least 5 rabbits. All myocytes were isolated from captopril-treated rabbits with the exception of 6 isolated from untreated controls (Con). Pipette filling solutions contained PKCvarepsilon -inhibiting, scrambled PKCvarepsilon -inhibiting (varepsilon -scr), psi varepsilon RACK, or scrambled psi varepsilon RACK (psi epsilon RACK-scr) peptides in a concentration of 100 nM or they were peptide free. *Significant difference compared with mean Ip of myocytes from captopril-treated rabbits not exposed to 1 µM ANG II in superfusate and/or peptide in pipette solution (Cap).

Effect of PKC inhibition on the response of Ip to ANG II. ANG II predominantly induces translocation of the classical PKC isozymes and the novel varepsilon -isozyme. Of these, the Ca2+-insensitive PKCvarepsilon is more likely to be involved in a response elicited in myocytes exposed to a nominally Ca2+-free superfusate at the extracellular surface and to an EGTA-containing patch pipette solution perfusing the intracellular compartment. We examined the effect of blockade of PKCvarepsilon . We patch clamped myocytes isolated from captopril-treated rabbits using pipettes with a filling solution that included a PKCvarepsilon -blocking peptide (EAVSLKPT). After the whole cell configuration was achieved, myocytes were exposed to ANG II before Ip was determined, as described for experiments performed without a PKCvarepsilon -blocking peptide in pipette solutions. Figure 1 includes a representative trace of membrane currents. Ip was similar to the Ip for the myocyte not exposed to ANG II (Fig. 1, top). The mean level of Ip of all experiments performed using both ANG II-containing superfusates and a PKCvarepsilon -blocking peptide in pipette solutions is shown in Fig. 2. The peptide abolished the effect of ANG II on Ip.

The effect of the PKCvarepsilon -blocking peptide shown in Fig. 2 might be due to direct stimulation of Ip by the peptide opposing the expected ANG II-induced decrease, independent of the mechanism mediating the decrease in Ip. To examine this, we again patch clamped myocytes from captopril-treated rabbits using a pipette solution that contained PKCvarepsilon -blocking peptide. However, the superfusates used before we measured Ip did not contain ANG II. The mean level of Ip, shown in Fig. 2, was similar to the level for myocytes from captopril-treated rabbits not exposed to ANG II and PKCvarepsilon -blocking peptide. This indicates that the peptide does not directly stimulate Ip in myocytes from captopril-treated rabbits.

To examine whether the ability of PKCvarepsilon -blocking peptide to abolish the ANG II-induced decrease in Ip is due to a nonspecific effect of the charge on the peptide influencing charged groups on the pump molecule, we used a scrambled form of the peptide (LSETKPAV). We patch clamped myocytes from captopril-treated rabbits using pipette solution containing 100 nM scrambled PKCvarepsilon -blocking peptide. The myocytes were exposed to ANG II before Ip was measured. The mean level of Ip, included in Fig. 2, was similar to levels of Ip for myocytes exposed to ANG II and patch clamped using peptide-free pipette solutions. This indicates that the amino acid sequence of the PKCvarepsilon -blocking peptide is essential for the effect on the ANG II-induced decrease in Ip.

Effect of PKCvarepsilon activation on Ip. To examine whether the effect of ANG II on Ip could be reproduced by directly activating PKCvarepsilon , we patch clamped myocytes from captopril-treated rabbits using pipette solutions that contained 100 nM of the agonist psi varepsilon RACK (HDAPIGYD) (7). The myocytes were not exposed to ANG II before Ip was determined. The mean level of Ip, included in Fig. 2, was similar to levels for myocytes exposed to ANG II and myocytes that were patch clamped using pipette solutions free of activating peptide. To examine whether the decrease in Ip was caused by a nonspecific effect of the charge of psi varepsilon RACK, we performed experiments using 100 nM of a scrambled form of the peptide (PDYHDAGI) in pipette filling solutions. It had no effect on Ip (Fig. 2). We next examined whether there was an additive effect of ANG II and psi varepsilon RACK. We patch clamped myocytes from captopril-treated rabbits using pipette solutions that contained psi varepsilon RACK. The myocytes were exposed to ANG II before Ip was measured. The mean level of Ip, shown in Fig. 2, was similar to the mean level of myocytes exposed to ANG II in the superfusate only or to psi varepsilon RACK in pipette solution only.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ANG II induces translocation in cardiac and noncardiac cells of the classical PKCalpha -, PKCbeta 2-, and PKCgamma -isoforms (4, 13, 27), the novel PKCvarepsilon -isoform (13, 18, 22, 23, 25, 27), and the atypical PKCzeta -isoform (15, 27). The ANG II-induced decrease in Ip is blocked by 20 nM staurosporine (10) and mimicked by exposure of myocytes to phorbol 12-myristate 13-acetate (PMA) (1, 10). Staurosporine, in a concentration of 20 nM, has little if any effect on PKCzeta (9), and PMA does not activate atypical PKC isozymes (3, 9). The Ca2+-dependent alpha -, beta 2-, and gamma -isozymes may be blocked under the conditions of the present study. These considerations do not rule out a role for the Ca2+-dependent isozymes or PKCzeta in mediating the ANG II-induced decrease in Ip. However, in combination with reports indicating that ACE inhibitors and ANG II receptor antagonists prevent translocation of PKCvarepsilon in the heart (17, 23, 26), other researchers sought to justify a focus on PKCvarepsilon in search of a specific isozyme regulating the Na+-K+ pump.

We used peptides that interfere with translocation of PKC. Upon activation, PKC is translocated from binding sites in the cytoplasm to isozyme-specific receptors for activated kinase (RACK). Peptides that mimic the binding sites on RACKs or PKC prevent translocation and inhibit kinase activity (see Refs. 3 and 19 for review). To introduce a PKCvarepsilon -blocking peptide into the intracellular compartment, we included the peptide in the patch pipette solution. For the volume of rabbit myocytes (6) used, equilibration of a molecule the size of the peptide is expected to be completed in the 4 min that elapsed from the time the whole cell configuration was established until myocytes were exposed to ANG II (calculated according to Ref. 24). The PKCvarepsilon -blocking peptide in the concentration we used or in a lower estimated intracellular concentration completely blocked translocation and activation of PKCvarepsilon (12) in cardiac myocytes and functional responses mediated by the isozyme (7, 12, 16). We also examined the effect of psi varepsilon RACK, a peptide designed to bind to cytosolic isozyme-specific anchoring proteins, displace PKC, and cause its translocation to RACKs (7). The peptide, in a concentration lower than that which we used, induced translocation of PKCvarepsilon in cardiac myocytes similar to the translocation induced by the robust stimulus of 100 nM PMA (7).

PKCvarepsilon -blocking peptide and psi varepsilon RACK are highly specific for inhibiting (12, 32) and activating (7) PKCvarepsilon . The effect of the blocking peptide shows that activation of PKCvarepsilon is necessary for ANG II to induce a decrease in Ip, and the effect of psi varepsilon RACK shows that activation of PKCvarepsilon is sufficient to induce a decrease in Ip without concomitant activation of ANG II receptors. If ANG II receptors and PKCvarepsilon were linked to the Na+-K+ pump via separate pathways, there might be an additive effect of ANG II and activation of PKCvarepsilon on Ip. There was no such additive effect (Fig. 2). In general, stimuli initiate activation and interaction of multiple cellular messengers in a complex "network" of pathways (see Refs. 2 and 20 for review). The present study does not rule out participation of PKC isozymes other than PKCvarepsilon or other cellular messengers in the pathways controlling the sarcolemmal Na+-K+ pump. However, it has established that PKCvarepsilon is likely to play an important role.

The effect of PKC on the Na+-K+ pump has been extensively studied (see Ref. 30 for recent comprehensive review). The isolated, purified enzymatic equivalent of the Na+-K+ pump, Na+-K+-ATPase, can be phosphorylated at specific amino acid residues by PKC in vitro, and phorbol ester-induced activation of PKC in intact cells is associated with phosphorylation of Na+-K+ pumps in intact cells. It is tempting to assume that PKC-dependent regulation of the pump is a direct consequence of phosphorylation of the pump molecule. However, this assumption is not universally supported (see Ref. 30 for discussion).

There are also serious discrepancies between studies regarding the effect of PKC on the function of the Na+-K+ pump. Stimulation, inhibition, and the absence of any effect have been reported. A variety of different tissues have been studied; phorbol esters or diacylglycerol analogs have been used to activate PKC, and pharmacological blockers with no isoform specificity have been used to inhibit PKC. Tissue-dependent expression of PKC isoforms and isoform-specific response to experimental stimulation and inhibition may have contributed to the controversy regarding regulation of the pump by PKC. Isoform specificity should be taken into account when studying the effect of PKC on the Na+-K+ pump (30).

The mechanisms proposed for the effect of PKC on the pump vary widely. For studies reporting a PKC-induced decrease in pump activity, the mechanisms include internalization of Na+-K+ pumps and a change in the pump's apparent affinity for Na+ (30). A decrease in Ip secondary to internalization of pump units should be independent of the compositions of pipette solutions. However, a PKC-induced internalization of pumps is unlikely since the decrease in Ip depends on the presence of K+ in the solutions at the time Ip is measured (1).

We have previously shown that the dependence of the ANG II-induced decrease in Ip on intracellular K+ suggests regulation of competitive inhibition by K+ of pump activation by Na+ at sites near the cytoplasmic surface. This K+/Na+ antagonism effectively contributes to regulation of the apparent affinity of the pump for Na+ (1). The effect of PKCvarepsilon on this antagonism may not be detected experimentally unless the intracellular Na+ concentration is carefully controlled at nonsaturating levels and intracellular K+ or K+ congeners are present. This has not been taken into account in previous studies. The inhibitory effect of K+ at cytosolic pump sites is particularly pronounced in cardiac tissue and may be variable and subject to regulation by some cellular component(s) (29). The present study implicates PKCvarepsilon as one such component.

Regulation of the Na+-K+ pump may interact with PKCvarepsilon in the pathogenic cardiac disease processes. Overexpression of PKCvarepsilon (28) or of the psi varepsilon RACK peptide (21) causes cardiac hypertrophy in transgenic animal models. Pump inhibition induced by PKCvarepsilon may contribute to the hypertrophic process, an effect that may be amplified because an increase in the intracellular Na+ concentration in cardiac myocytes induces translocation of PKCvarepsilon (8). Cause-effect relationships between Na+-K+ pump inhibition, activation of PKCvarepsilon , and cardiac hypertrophy cannot be established at present. However, from a therapeutic perspective, it may be important that ACE inhibitors and ANG II receptor antagonists can prevent translocation of PKCvarepsilon in the heart (17, 23, 26). They can also induce a pump-mediated decrease in intracellular Na+ levels (11). These effects might interrupt a PKCvarepsilon -Na+-K+ pump interaction that contributes to the complex network of stimuli causing hypertrophy. It is consistent with these speculations that ACE inhibitors and ANG II receptor antagonists have considerable efficacy in prevention and treatment of cardiac hypertrophy.


    ACKNOWLEDGEMENTS

This study was supported by National Heart Foundation of Australia Grant G96S 4589 and by the North Shore Heart Research Foundation.


    FOOTNOTES

Address for reprint requests and other correspondence: H. Rasmussen, Dept. of Cardiology, Royal North Shore Hospital, Pacific Highway, St. Leonards, Sydney, New South Wales, Australia 2065 (E-mail: Helger{at}med.usyd.edu.au).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 1 August 2000; accepted in final form 6 April 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Buhagiar, KA, Hansen PS, Gray DF, Mihailidou AS, and Rasmussen HH. Angiotensin regulates the selectivity of the Na+-K+ pump for intracellular Na+. Am J Physiol Cell Physiol 277: C461-C468, 1999[Abstract/Free Full Text].

2.   Bhalla, US, and Iyengar R. Emergent properties of networks of biological signalling pathways. Science 283: 381-387, 1998[Abstract/Free Full Text].

3.   Csukai, M, and Mochly-Rosen D. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol Res 39: 253-259, 1999[ISI][Medline].

4.   Damron, DS, Nadim HS, Jin Hong S, Darvish A, and Murray PA. Intracellular translocation of PKC isoforms in canine pulmonary artery smooth muscle cells by ANG II. Am J Physiol Lung Cell Mol Physiol 274: L278-L288, 1998[Abstract/Free Full Text].

5.   Dempsey, EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Nissel PA, and Messing RO. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279: L429-L438, 2000[Abstract/Free Full Text].

6.   Doohan, MM, Gray DF, Hool LC, Robinson BG, and Rasmussen HH. Thyroid status and regulation of intracellular sodium in rabbit heart. Am J Physiol Heart Circ Physiol 272: H1589-H1597, 1997[Abstract/Free Full Text].

7.   Dorn, GW, II, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, and Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed peptide that causes varepsilon  protein kinase C translocation. Proc Natl Acad Sci USA 96: 12798-12803, 1999[Abstract/Free Full Text].

8.   Hayasaki-Kajiwara, Y, Kitano Y, Iwasaki T, Shimamura T, Noriyuki N, Iwaki K, and Nakajima M. Na+ influx via Na+/H+ exchange activates protein kinase C isozymes delta  and epsilon  in cultured neonatal rat cardiac myocytes. J Mol Cell Cardiol 31: 1559-1572, 1999[ISI][Medline].

9.   Hofmann, J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J 11: 649-669, 1997[Abstract/Free Full Text].

10.   Hool, LC, Gray DF, Robinson BG, and Rasmussen HH. Angiotensin-converting enzyme inhibitors regulate the Na+-K+ pump via effects on angiotensin metabolism. Am J Physiol Cell Physiol 271: C172-C180, 1996[Abstract/Free Full Text].

11.   Hool, LC, Whalley DW, Doohan MM, and Rasmussen HH. Angiotensin-converting enzyme inhibition, intracellular Na+, and Na+-K+ pumping in cardiac myocytes. Am J Physiol Cell Physiol 268: C366-C375, 1995[Abstract/Free Full Text].

12.   Johnson, JA, Gray MO, Chen CH, and Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem 271: 24962-24966, 1996[Abstract/Free Full Text].

13.   Karim, Z, Defontaine N, Paillard M, and Poggioli J. Protein kinase C isoforms in rat kidney proximal tubule: acute effect of angiotensin II. Am J Physiol Cell Physiol 269: C134-C140, 1995[Abstract/Free Full Text].

14.   Kometiani, P, Li J, Gnudi L, Kahn BB, Askari A, and Xie Z. Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and the mitogen-activated protein kinases. J Biol Chem 273: 15249-15256, 1998[Abstract/Free Full Text].

15.   Liao, DF, Monia B, Dean N, and Berk BC. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 272: 6146-6150, 1997[Abstract/Free Full Text].

16.   Liu, GS, Cohen MV, Mochly-Rosen D, and Downey JM. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiac myocytes. J Mol Cell Cardiol 31: 1937-1948, 1999[ISI][Medline].

17.   Malhotra, A, Reich D, Reich D, Nakouzi A, Sanghi V, Geenan DL, and Buttrick PM. Experimental diabetes is associated with functional activation of protein kinase Cepsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res 81: 1027-1033, 1997[Abstract/Free Full Text].

18.   Maloney, JA, Tsygankova O, Szot A, Yang L, Li Q, and Williamson JR. Differential translocation of protein kinase C isozymes by phorbol esters, EGF and ANG II in rat liver WB cells. Am J Physiol Cell Physiol 274: C974-C982, 1998[Abstract/Free Full Text].

19.   Mochly-Rosen, D, and Gordon AS. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J 12: 35-42, 1998[Abstract/Free Full Text].

20.   Mochly-Rosen, D, and Kauvar LM. Modulating protein kinase C signal transduction. Adv Pharmacol 44: 44-91, 1998.

21.   Mochly-Rosen, D, Wu G, Hahn H, Osinaka H, Liron T, Lorenz JN, Yatani A, Robbins J, and Dorn GW II. Cardiotrophic effects of protein kinase Cepsilon . Analysis by in vivo modulation of PKCepsilon translocation. Circ Res 86: 1173-1179, 2000[Abstract/Free Full Text].

22.   Natarajan, R, Lanting L, Xu L, and Nadler J. Role of specific isoforms of protein kinase C in angiotensin II and lipoxygenase action in rat adrenal glomerulosa cells. Mol Cell Endocrinol 101: 59-66, 1994[ISI][Medline].

23.   Paul, K, Ball NA, Dorn GW, and Walsh RA. Left ventricular stretch stimulates angiotensin II-mediated phosphatidylinositol hydrolysis and protein kinase Cepsilon isoform translocation in adult guinea pig hearts. Circ Res 81: 643-650, 1997[Abstract/Free Full Text].

24.   Pusch, M, and Neher E. Rates of diffusional exchange between small cells and a measuring patch pipette. Pflügers Arch 411: 204-311, 1988[ISI][Medline].

25.   Schunkert, H, Sadoshima J, Cornelius T, Kagaya Y, Weinberg EO, Izumo S, Riegger G, and Lorell BH. Angiotensin II-induced growth responses in isolated adult rat hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 76: 489-497, 1995[Abstract/Free Full Text].

26.   Takeishi, Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, and Walsh RA. Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol Heart Circ Physiol 276: H53-H62, 1999[Abstract/Free Full Text].

27.   Takeishi, Y, Jalili T, Ball NA, and Walsh RA. Responses of cardiac protein kinase C isoforms to distinct pathological stimuli are differentially regulated. Circ Res 85: 264-271, 1999[Abstract/Free Full Text].

28.   Takeishi, Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, and Walsh RA. Transgenic overexpression of constitutively active protein kinase C causes concentric cardiac hypertrophy. Circ Res 86: 1218-1223, 2000[Abstract/Free Full Text].

29.   Therien, AG, and Blostein R. K+/Na+ antagonism at cytoplasmic sites of Na+-K+-ATPase: a tissue-specific mechanism of sodium pump regulation. Am J Physiol Cell Physiol 277: C891-C898, 1999[Abstract/Free Full Text].

30.   Therien, AG, and Blostein R. Mechanisms of sodium pump regulation. Am J Physiol Cell Physiol 279: C541-C566, 2000[Abstract/Free Full Text].

31.   Xie, Z, Kometiani P, Liu J, Li J, Shapiro JI, and Askari A. Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 274: 19323-19328, 1999[Abstract/Free Full Text].

32.   Yedovitsky, M, Mochly-Rosen D, Johnson JA, Gray MO, Ron D, Abramowitch E, Cerasi E, and Nesher R. Translocation inhibitors define specificity of protein kinase C isozymes in pancreatic beta -cells. J Biol Chem 272: 1417-1420, 1997[Abstract/Free Full Text].


Am J Physiol Cell Physiol 281(3):C1059-C1063
0363-6143/01 $5.00 Copyright © 2001 the American Physiological Society